Lisa J. McReynolds, M.D., Ph.D., joined the Clinical Genetics Branch (CGB) as a clinical fellow in 2016, was promoted to assistant clinical investigator in 2019 and became a Lasker Clinical Research Scholar in 2024. She earned her M.D. and Ph.D. at Albert Einstein College of Medicine, where she studied Smad signaling in a zebrafish model of hematopoiesis in the laboratory of Todd Evans, Ph.D. (2009). Dr. McReynolds then completed a residency in pediatrics at Morgan Stanley’s Children’s Hospital of New York-Presbyterian Hospital and fellowship through the joint program of Johns Hopkins
MD, PhD. My main scientific interests concern germline predisposition to bone marrow failures and myeloid neoplasms, particularly to myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML). I am also deeply intrigued by the intersection of inborn errors of immunity (IEIs) and hemopathies.
Matteo Giovanni Della Porta is head of Leukemia Unit at Humanitas Cancer Center in Milan, where he is also the head of the Genomics of Hematological Neoplasms Lab. He is full professor of Hematology at Humanitas University and director of the Center for Acclelerating Leukemia/Lymphoma Research, a joint effort from Humanitas University, Humanitas Research Hospital, Humanitas AI Center and the Politecnico di Milano. He obtained his Medical Degree with honors at the University of Pavia Medical School, Italy in 1999. From 2000 to 2003 he completed his training in Hematology at the Department of
In this issue of Blood, Mushtaq et al1 report on a phase 1/2 trial (NCT05984199, known as Vor Biopharma trial VBP301) utilizing donor-derived anti-CD33 chimeric antigen receptor–modified (CAR) T cells (VCAR33) in patients with relapsed acute myeloid leukemia (AML) following…
Abstract Selection of a hematopoietic progenitor cell donor for allogeneic hematopoietic cell transplantation (HCT) is essential for treatment planning; however, the parameters that define an “optimal” donor in the modern era are not well defined. Historically, donor-recipient…
Abstract The diagnosis and treatment of hematologic malignancies has undergone significant advancements over the past few decades, resulting in enhanced outcomes. For hematologic malignancies diagnosed during pregnancy, this poses new questions. As possibilities continue to…
Abstract Venetoclax (Ven) in combination with hypomethylating agents (HMA) (azacitidine or decitabine) is the standard of care for elderly or unfit patients with acute myeloid leukemia (AML) and is being explored in high-risk myelodysplastic syndrome (HR-MDS). However, currently…
Patients who receive hematopoietic stem cell transplants are at risk of developing graft-versus-host disease (GVHD), where the immune cells descended from the transplanted stem cells attack the transplant recipient’s own tissues. Acute GVHD (aGVHD) is often treated with…
Abstract The comparative value of liposomal cytarabine/daunorubicin (CPX-351) versus venetoclax plus a hypomethylating agent (Ven-HMA) in the frontline treatment of older adults with primary (de novo) or secondary acute myeloid leukemia (AML) remains uncertain. In the current…